NuVasive received FDA 510(k) clearance and CE Mark approval to market Precice® Bone Transport, an all-internal treatment for segmental bone loss in the tibia and femur.
Seikagaku and Ono Pharmaceutical obtained positive topline results from a Phase III confirmatory study of an HA/NSAID formulation in the treatment of knee OA.